Kai-Xian Chen has sold ZLAB and made no open-market buys since Mar 2021

Professor Kai-Xian Chen, Ph.D. is a seasoned scientific leader and corporate insider who has served as a director of Zai Lab Ltd (ZLAB), an innovative biopharmaceutical company focused on developing and commercializing therapies for oncology, autoimmune, and infectious diseases.( He joined Zai Lab’s Board of Directors in August 2018 and served as a member of the Research & Development Committee, bringing extensive experience in drug research and development in China.( In this role, he also oversaw his equity holdings in the company, including reported sales of American Depositary Shares in 2023 and 2024 to cover tax obligations.( Dr. Chen resigned as an independent non-executive director and member of the Research & Development Committee effective December 31, 2024, in order to devote more time to other professional and personal activities.(

Chen’s professional background is rooted in a distinguished academic and research career in medicinal chemistry and drug design.( He has long served as a professor at the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and at Shanghai University of Traditional Chinese Medicine, previously holding senior leadership roles including President of Shanghai University of Traditional Chinese Medicine and Director of SIMM.( He has been a member of the Chinese Academy of Sciences since 1999 and has played key advisory roles in major national science and technology projects on innovative drugs and modernization of traditional Chinese medicine across multiple PRC Five-Year Plans.( Chen completed his postdoctoral research at Institut de Biologie Physico-Chimique in Paris, earned his Master’s and Ph.D. degrees from the Chinese Academy of Sciences, and holds a Bachelor of Science in radiochemistry from Fudan University.( In addition to Zai Lab, he serves on the boards of other biopharmaceutical companies, including Innovent Biologics, Jiangsu Kanion Pharmaceutical, and InnoCare Pharma, further underscoring his influence in China’s pharmaceutical innovation ecosystem.(

Written by Perplexity from public sources.